Shots:

• invoX (a UK subsidiary of Chinese Sino Biopharma) to acquire all of the issued & outstanding shares of F-star common stock at $7.12/share making a total deal value of ~$161M. The transaction is expected to be close in H2’22
• The acquisition will boost invoX’s strategy to establish Sino's international biopharmaceutical R&D platform outside of China & improves the patients’ QoL. F-star has partnered with large multinational biopharma companies across therapeutic areas by using its Ab technology
• F-star’s tetravalent (2+2) bispecific Ab platform complements Sino's capabilities & reinforces its global oncology pipeline.  The platform allows the target of 2 separate Ag & set of pharmacology to offer targeted, powerful & secure immune activation in the tumor microenvironment

Ref: GlobalNewswire | Image: invoX